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Silent information regulator 2 proteins (sirtuins or SIRTs) are a group of deacetylases (or
deacylases) whose activities are dependent on and regulated by nicotinamide adenine
dinucleotide (NAD+). Compelling evidence supports that sirtuins play major roles in many
aspects of physiology, especially in pathways related to aging – the predominant and
unifying risk factor for neurodegenerative diseases. In this review, we highlight the
molecular mechanisms underlying the protective effects of sirtuins in neurodegenerative
diseases, focusing on protein homeostasis, neural plasticity, mitochondrial function, and
sustained chronic inﬂammation. We will also examine the potential and challenges of
targeting sirtuin pathways to block these pathogenic pathways.
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INTRODUCTION
The past decade has seen an explosion of studies of sirtuins in
health and disease. The foundingmember of the sirtuin gene fam-
ily Sir2 was originally found in yeast, but others have since been
found in many organisms (Kaeberlein et al., 1999). Mammalian
sirtuins have seven homologs (SIRT1–7) that share a conserved
catalytic core domain as class III histone deacetylases (HDACs) but
exhibit different enzymatic activities in distinct subcellular local-
izations. Unlike class I and II HDACs, which require only zinc as
a cofactor, sirtuins depend on NAD+ for activity. In the presence
of NAD+, sirtuins catalyze the conversion of an acetylated sub-
strate to a deacetylated substrate with O-acetyl-ADP-ribose and
nicotinamide as side products.
SIRT1 shares the greatest homology with yeast Sir2 (Frye,
2000). In addition to histones, SIRT1 catalyzes deacetylation
of a large number of non-histone substrates in the nucleus
and cytoplasm. It is involved in diverse cellular functions,
including maintaining genomic stability, suppressing inﬂam-
mation, enhancing synaptic plasticity, and protecting against
neurodegeneration. Like SIRT1, SIRT2 is a strong deacetylase
with some common substrates in the cytoplasm and nucleus
(Donmez and Outeiro, 2013). SIRT3–5 are localized mainly in
the mitochondria. SIRT3 is the major mitochondrial deacety-
lase with a broad range of substrates (Newman et al., 2012).
SIRT4 is a mitochondrial ADP-ribosyltransferase without any
recognized deacetylase activity, and SIRT5 is both an NAD+-
dependent deacetylase and deacylase (demalonylase and desuc-
cinylase; Du et al., 2011). Localized exclusively in the nucleus,
SIRT6 is a chromatin-bound NAD+-dependent deacetylase and
anADP-ribosyltransferase. SIRT7 is localized to the nucleolus and
regulates ribosomal DNA gene expression (Ford et al., 2006; Jia
et al., 2012; Table 1).
Earlier studies showed that the lifespan of yeast was shortened
by deleting Sir2, but lengthened by its overexpression (Kae-
berlein et al., 1999). Increased dosages of the Sir2 orthologs,
SIR-2.1 and dSIR2, also extended lifespan of worm (Tissenbaum
and Guarente, 2001) and ﬂy (Rogina and Helfand, 2004). Most
recently, the anti-aging role of Sir2 has been challenged and reﬁned
(Burnett et al., 2011; Viswanathan and Guarente, 2011; Banerjee
et al., 2012). Nevertheless, compelling evidence supports a major
role for sirtuins in many aspects of physiology from protozoa to
metazoan (Michan and Sinclair, 2007; Baur et al., 2012; Libert and
Guarente, 2013).
This review focuses on our current understanding of the
role of sirtuins in several instrumental pathogenic processes
in neurodegenerative diseases, with special emphasis on pro-
tein homeostasis, neural plasticity, mitochondrial function, and
inﬂammatory pathways.
PROTEIN HOMEOSTASIS
Neurodegenerative diseases have distinct clinical manifestations,
mostly due to the impairment of speciﬁc neural networks. How-
ever, they share key features, one of which is loss of protein
homeostasis in the form of intra- or extracellular accumulation of
soluble and insoluble protein aggregates. These protein aggregates
are hallmarks of the disease and include amyloid β (Aβ), hyper-
phosphorylated tau, cytosolic TDP-43, α-synuclein, huntingtin,
and others.
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Table 1 | Subcellular localizations and catalytic activities of
mammalian sirtuins.
Subcellular localization Catalytic activity
SIRT1 Nucleus, cytoplasm Deacetylase
SIRT2 Nucleus, cytoplasm Deacetylase
SIRT3 Mitochondria Deacetylase
SIRT4 Mitochondria ADP-ribosyltransferase
SIRT5 Mitochondria Deacetylase, deacylase
SIRT6 Nucleus Deacetylase, ADP-ribosyltransferase
SIRT7 Nucleolus Deacetylase
Alzheimer’s disease (AD) is the most common dementia in the
elderly population. Aβ peptides are believed to be a key culprit in
AD (Hardy and Selkoe, 2002). Although amyloid plaques are well-
recognized pathological hallmarks inAD brains, speciﬁc types and
forms of soluble Aβ oligomers have been implicated as the earliest
triggers in the amyloid toxicity pathway (Klein, 2002; Lesne et al.,
2006; Querfurth and LaFerla, 2010). The amyloid hypothesis is
strongly supported by human genetic analyses: the vast major-
ity of familial mutations that cause early-onset AD are associated
with increased production of Aβ peptides, leading to imbalance in
homeostatic control of protein levels (Tanzi andBertram,2005). In
contrast, a codingmutation that protects against AD and cognitive
decline also reduces the production of Aβ by 40% (Jonsson et al.,
2013). SIRT1 lowers Aβ levels by reducing its production from
amyloid precursor protein (APP). Cleavage of APP by α-secretase
results in production of non-amyloidogenic fragments, and cleav-
age by β- and γ-secretases results in various Aβ and C-terminal
fragments (Hardy and Selkoe, 2002). In cultured cells, SIRT1
enhances α-secretase activity via inhibiting the Rho-associated,
coiled-coil-containing protein kinase 1 (ROCK), and reduces Aβ
production (Figure 1; Qin et al., 2006). A more recent study
showed that SIRT1 also enhances the transcription of ADAM10, a
FIGURE 1 | Protective mechanisms of SIRT1 in AD. SIRT1 deacetylates tau
protein at multiple residues, and enhances tau polyubiquitination and
subsequent proteasomal degradation. Overexpression of SIRT1 deacetylates
retinoic acid receptor (RAR) β and activates ADAM10, a component of the
α-secretase, which processes APP along an anti-amyloidogenic pathway that
decreases formation of toxic Aβ species. SIRT1 was also shown to enhance
α-secretase cleavage via a mechanism involving reducing ROCK1, which
suppresses α-secretase cleavage.
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member of α-secretase family, by deacetylating and activating the
retinoic acid receptor β (Donmez et al., 2010; Figure 1).
Hyperphosphorylated tau accumulates in the formof neuroﬁb-
rillary tangles in neurodegenerative tauopathies, including AD
and frontotemporal lobar degeneration with tau-positive inclu-
sions (FTLD-tau; Cairns et al., 2007; Ludolph et al., 2009). In
AD, the number and extent of neuroﬁbrillary tangles are the best
pathological hallmark correlating with the severity of cognitive
impairments and neurodegenerations whereas the plaque loads do
not correlate at all with regional atrophy and synaptic loss (Berg
et al., 1998). SIRT1 levels correlate negatively with the amount of
neuroﬁbrillary tangles in AD brains (Julien et al., 2009), and this
association suggests a possible pathogenic role of SIRT1 deﬁciency
in tau accumulation. Indeed, tau was acetylated in the early and
late stages of tauopathies (Min et al., 2010; Cohen et al., 2011; Irwin
et al., 2012; Grinberg et al., 2013). Aberrant tau acetylation has a
key role in tau accumulation and dysfunction (Min et al., 2010;
Cohen et al., 2011; Irwin et al., 2012; Grinberg et al., 2013). SIRT1
deacetylates tau, and its deﬁciency results in enhanced levels of
acetylated tau and phosphorylated tau (Min et al., 2010; Figure 1).
α-Synuclein has been implicated in several neurodegenerative
diseases, including dementiawith Lewy bodies, Parkinson’s disease
(PD), and multiple system atrophy (Goedert et al., 2013). SIRT1
suppresses the formation of α-synuclein inclusions in Caenorhab-
ditis elegans (van Ham et al., 2008). Treatment with resveratrol,
an indirect activator of SIRT1, protected cells of the human
neuroblastoma line SK-N-BE against toxicity induced by expres-
sion of α-synuclein carrying familial PD mutation (A30P; Albani
et al., 2009). This protective mechanism depends on SIRT1; treat-
ment with sirtinol, a speciﬁc inhibitor of SIRT1, restored toxicity.
SIRT1 reduced the number of α-synuclein aggregates in the brains
of mice expressing A53T α-synuclein. SIRT1 deacetylates heat
shock factor-1 (Westerheide et al., 2009), resulting in an increased
expression of Hsp70, a molecular chaperon that could serve as
a protective mechanism against α-synuclein toxicity (Donmez
et al., 2012). In contrast, inhibiting SIRT2 rescued α-synuclein-
mediated toxicity and modiﬁed aggregation in models of PD in
vitro (Outeiro et al., 2007). The opposing effects of SIRT1 and
SIRT2 on synucleinopathies could reﬂect their distinct subcellular
localizations and substrates.
In mammalian cells, misfolded proteins can be removed by the
proteasome or the autophagy–lysosomal pathways. Since acetyla-
tion and ubiquitination both occur at lysine residues, acetylation
often interferes with polyubiquitination, which is required for
proteasome-mediated degradation. Thus, lack of SIRT1 induces
hyperacetylation of the substrate proteins, which preclude them
from the polyubiquitination process, resulting in increased steady-
state protein levels. For example, inhibition of SIRT1 blocks
tau polyubiquitination and tau turnover, likely via increased
acetylation of tau on lysine residues that are also subject to
polyubiquitination (Min et al., 2010).
SIRT1 deacetylates autophagy gene products and stimulates
basal rates of autophagy (Lee et al., 2008), which has emerged
as an important route for the removal of toxic misfolded protein
aggregates that accumulate in neurodegenerative diseases (Levine
and Kroemer, 2008). Autophagy induced by SIRT1 activation pre-
vented neurotoxicity by prion protein fragment (106–126) in a
neuronal cell line (Jeong et al., 2013). Degradation of α-synuclein
was also enhanced by SIRT1 activator via autophagy induction in
α-synuclein-expressing PC12 cell lines (Wu et al., 2011). In agree-
ment with these ﬁndings in mammalian cells, Sir2 promotes both
autophagy and mitophagy in Saccharomyces cerevisiae (Sampaio-
Marques et al., 2012). In contrast to the autophagy-enhancing
effects of SIRT1, SIRT2 inhibits the autophagy-mediated degra-
dation of protein aggregates in neuronal cell lines (Gal et al.,
2012). In a neuronal cell line, overexpression of SIRT2 inhibits
lysosome-mediated autophagic turnover of protein aggregates and
exacerbates toxicity induced by Aβ (Gal et al., 2012).
NEURONAL PLASTICITY
Regulation of the formation andmaintenance of memory involves
epigenetic mechanisms, such as post-translational modiﬁcations
of histone tails, DNA methylation, and non-coding RNA (Fischer
et al., 2007; Day and Sweatt, 2011;Wang et al., 2012). Brain-speciﬁc
SIRT1 knockout mice showed deﬁcits in learning and memory,
supporting the importance of SIRT1 in maintaining neural plas-
ticity (Gao et al., 2010). Whether and how other sirtuins might
regulate neural plasticity remains to be determined.
Brain-derived neurotrophic factor (BDNF),which plays a criti-
cal role in neural plasticity (Lipsky andMarini, 2007), is enhanced
by SIRT1 (Gao et al., 2010). Speciﬁcally, it increases the number
of dendritic spines, neuronal connectivity, and memory function.
SIRT1 deﬁciency reduces BDNF expression by upregulating the
microRNA miR-134 (Gao et al., 2010). SIRT1 forms a repressor
complex with the transcription factor YY1 to suppress miR-134
expression (Gao et al., 2010). Anothermechanism by which SIRT1
regulates BDNF involves deacetylation of methyl-CpG binding
protein 2 (MeCP2). This action allows MeCP2 to be released
from the methylated CpG sites within the BDNF exon 4 pro-
moter, resulting in increased BDNF transcription in hippocampus
(Zocchi and Sassone-Corsi, 2012).
The importance of cAMP response element-binding protein
(CREB) as a crucial regulator for learning and memory process is
conserved from mollusk neurons in culture to complex behav-
iors in mammals (Bliss and Collingridge, 1993; Alberini et al.,
1994). Like BDNF, SIRT1 enhances CREB expression through the
miR-134 pathway (Gao et al., 2010). SIRT1 directly deacetylates
CREB and modulates its activity in liver (Qiang et al., 2011) but
not in brain (Fusco et al., 2012). CREB is involved in the brain’s
response to CR, which upregulates SIRT1 levels. Increased SIRT1
levels, in turn, enhance CREB-dependent expression of genes
involved in neuronal metabolism, survival, and plasticity (Fusco
et al., 2012). Although the exact molecular mechanism underly-
ing the CREB–SIRT1 axis is unknown, these ﬁndings highlight a
unique molecular network at the crossroad of energy metabolism,
metabolic diseases, and brain aging.
MITOCHONDRIAL FUNCTIONS
Mitochondria are critical regulators of neuronal survival and
death. Theyproduce energy in response tonutrient availability and
are themain contributors of oxidative stress. Accumulating lines of
evidence suggest that disruption of mitochondrial processes leads
to neurodegenerative diseases (Lin and Beal, 2006). In a proteomic
survey of lysine acetylation, more than 20% of mitochondrial
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proteins are acetylated on their lysine residues (Newman et al.,
2012). This study supports the importance of modulatory role of
sirtuins as deacetylases in themaintenance of mitochondrial func-
tions. Most studies focused on SIRT1 and SIRT3 as the primary
regulators of mitochondrial biology via deacetylation (Brenmoehl
and Hoeﬂich, 2013). SIRT4 and SIRT5 are also localized in mito-
chondria. However, SIRT4 has only weak ADP ribosyltransferase
activity (Verdin et al., 2010), and SIRT5 regulates malonylation
and succinylation (Du et al., 2011). Indeed, SIRT3 knockout mice
display remarkable increases in the acetylation levels of mitochon-
drial proteins, whereas no mitochondrial hyperacetylation was
observed when the two other mitochondrial sirtuins, SIRT4 and
SIRT5, were deleted (Lombard et al., 2007).
SIRT1 deacetylates and activates PGC-1α, a transcriptional
coactivator that regulates several key mitochondrial processes,
including mitochondrial biogenesis and oxidative phosphoryla-
tion (Rodgers et al., 2005). SIRT1 also enhances transcription
of PGC-1α gene via interaction with MyoD, which binds to the
PGC-1α promoter (Amat et al., 2009). PGC-1α is required for the
induction of reactive oxygen species (ROS)-detoxifying enzymes.
PGC-1α null mice show high degree of sensitivity to the neu-
rodegenerative effects of oxidative stressors (St-Pierre et al., 2006).
In models of Huntington’s disease (HD), transcription of PGC-
1α is repressed by mutant huntingtin, the protein that causes
HD. PGC-1α knockout exacerbates neurodegeneration andmotor
abnormalities in the HD knockin mice. Conversely, PGC-1α
expression ameliorates, in part at least, mitochondrial dysfunc-
tion and neuronal toxicity induced by mutant huntingtin (Cui
et al., 2006). Elevating SIRT1 activity ameliorated neuronal dys-
function induced by mutant polyglutamines in C. elegans (Jiang
et al., 2012). Polyglutamine cytotoxicity is prevented by SIRT1 acti-
vation in neurons derived from HdhQ111 KI mice (Parker et al.,
2005). Inmousemodels of HD,ablation of SIRT1 exacerbates neu-
rodegeneration (Jeong et al., 2012), whereas SIRT1 overexpression
improves motor functions and brain atrophy (Jiang et al., 2012).
Thus, SIRT1 protects against HD-related neurodegeneration at
least partially by preventing mitochondrial impairment through
PGC-1α activation.
SIRT3 resides in the mitochondrial matrix and regulates the
acetylation of a number of metabolic enzymes in mitochon-
dria (Qiu et al., 2010). Because neurons have high demand in
cellular energy and limited regenerative capacity, mitochondrial
adaptation to changes in energy availability is a critical strat-
egy that protects neurons from degeneration (Andersen, 2004).
SIRT3 expression is responsive to changes in nutrient levels, and
its upregulation results in deacetylation of enzymes involved in
metabolic pathways that utilize alternative energy sources such as
fatty acids (Hynd et al., 2004; Someya et al., 2010). Pathogenic
protein accumulation can occur in mitochondria in AD neu-
rons, thereby disrupting mitochondrial electron transport chain
and increasing ROS production (Manczak et al., 2006). Increased
indices of ROS damage have been found in affected brain regions
of neurodegenerative diseases such as AD and PD (Andersen,
2004). SIRT3 deacetylates and increases activity of the super-
oxide dismutase SOD2 that reduces oxidative stress (Qiu et al.,
2010). A protective effect of SIRT3 against oxidative stress also
contributes to caloric restriction (CR)-mediated suppression of
degeneration of cochlear neurons (Someya et al., 2010).Mechanis-
tically, SIRT3 deacetylates and activates mitochondrial isocitrate
dehydrogenase 2, leading to increased levels of nicotinamide ade-
nine dinucleotide phosphate (NADPH), which in turn elevated
levels of reduced glutathione in mitochondria (Someya et al.,
2010). Mitochondrial SIRT3 is also regulated by various stresses in
neurodegenerative diseases. SIRT3 is upregulated by elevated lev-
els of ROS during excitotoxic stress (Hynd et al., 2004), a common
feature of neurodegenerative diseases, such AD. Upregulation of
SIRT3 protected against excitotoxicity (Kim et al., 2011). SIRT3
is also upregulated when ROS is pharmacologically augmented
in neuronal culture and in human AD brains (Weir et al., 2012).
Interestingly, SIRT3 levels were reduced in cells expressing mutant
huntingtin (Fu et al., 2012). SIRT3 upregulationmediated by small
molecules decreased levels of ROS and prevented mitochondrial
dysfunction and cytotoxicity induced by mutant huntingtin (Fu
et al., 2012).
INFLAMMATORY RESPONSES
In aging, genes involved in inﬂammatory responses are upregu-
lated in the human brain (Lu et al., 2004; Franceschi et al., 2007;
Krstic and Knuesel, 2013). On the other hand, CR, which acti-
vates sirtuin pathways, attenuates aging-induced upregulation of
inﬂammatory genes (Cao et al., 2001). These ﬁndings highlight
an intriguing connection between the anti-inﬂammatory func-
tion of sirtuins and their potent anti-aging effects. In addition,
many age-related neurodegenerative diseases, such as AD, fron-
totemporal dementias (FTD), amyotrophic lateral sclerosis (ALS),
and PD, exhibit prolonged inﬂammatory responses (Glass et al.,
2010). Thus, anti-inﬂammatory effects of sirtuins could have
broad relevance in aging and neurodegeneration.
Nuclear factor kappa B (NF-κB) is a master regulator of
immune response and inﬂammation (Hayden and Ghosh, 2012).
Bioinformatics analyses identiﬁed the NF-κB binding domain as
the motif most strongly associated with the aging process (Adler
et al., 2007). In the skin of aged mice, genetic blockade of NF-κB
reversed the global gene expression program and tissue character-
istics to those of young mice (Adler et al., 2008). The mechanism
might involve activation of redox-sensitive transcription factors
by the cumulative effects of oxidative damage during aging. For
example, the increased production of ROS during aging is associ-
ated with upregulation of NF-κB (Kabe et al., 2005). Activation of
NF-κB, in turn, induces the expression of proinﬂammatory genes,
including cytokines, growth factors, and chemokines (Mattson
and Meffert, 2006). Since some of the NF-κB-induced proteins
are also potent NF-κB activators, the resulting vicious cycle may
contribute to establishment of a chronic inﬂammatory state and
related pathologies.
NF-κB is also important in modulating cellular senescence.
Genetic reduction of p65 subunit or pharmacological inhibition
of NF-κB delayed the onset of progeroid symptoms in accelerated
agingmousemodel caused by a defect in DNA repair (Tilstra et al.,
2012). In human ﬁbroblasts, senescence induced by activation of
p16 and p53 resulted in global regulation of NF-κB pathways;
silencing of NF-κB overcame senescence (Rovillain et al., 2011).
Senescence is also suppressed by overexpressing SIRT1, which was
downregulated in the senescent cells (Rovillain et al., 2011). Thus,
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the beneﬁcial effects of SIRT1 on senescence are likely mediated
by inactivation of NF-κB pathways.
NF-κB-dependent transcription is repressed by SIRT1, which
deacetylates p65/RelA at lysine 310 (Yeung et al., 2004; Figure 2).
Macrophages derived from myeloid cell-speciﬁc SIRT1 knockout
mouse model had higher levels of proinﬂammatory cytokines
that are associated with NF-κB hyperacetylation (Schug et al.,
2010). In primary cortical cultures, microglial NF-κB activa-
tion played a critical role in Aβ-mediated neuronal death (Chen
et al., 2005). Increased expression of SIRT1 or treatment with
resveratrol markedly reduced Aβ-dependent NF-κB activation in
microglia and neuronal loss, suggesting that SIRT1 blocks the
neuropathogenic inﬂammatory loops (Chen et al., 2005; Figure 2).
NF-κB-dependent gene activation is strongly modulated by
poly(ADP-ribose) polymerase-1 (PARP-1), which possesses a
DNA binding domain enabling them to bind to damaged DNA
and thus become activated (Beneke, 2012). It consumes NAD+
in the process of forming (ADP-ribose) polymers on target pro-
teins (Canto et al., 2013). In cardiomyocytes, SIRT1 interacts
and deacetylates PARP-1, resulting in reduced PARP-1 activity
(Rajamohan et al., 2009). SIRT1 is also capable of suppressing
the activity of the PARP-1 gene promoter, leading to decreased
PARP-1 protein synthesis (Rajamohan et al., 2009). As PARP-1 is
required and sufﬁcient for speciﬁc transcriptional activation of
NF-κB, it is thus conceivable that SIRT1 could suppress NF-κB
signaling by reducing PARP-1 (Figure 2). Further studies will
be needed to establish the causative link. On the other hand,
since PARP-1 uses NAD+ as a substrate to synthesize PAR, exces-
sive PARP-1 activation could deplete NAD+ levels, resulting in
SIRT1 inhibition and NF-κB activation (Figure 2). In primary
astrocyte cultures, activation of PARP-1 with N-methyl-N ′-nitro-
N-nitrosoguanidine resulted in sustained acetylation of p65 and
NF-κB activation, likely by inhibiting SIRT1 due to depleted
NAD+ levels (Kauppinen et al., 2013). Consistent with this notion,
addition of exogenous NAD+ led to p65 deacetylation and inhi-
bition of NF-κB signaling (Kauppinen et al., 2013). In contrast,
inhibition of basal PARP-1 activity in myotubes and in muscle
raised NAD+ levels and enhanced SIRT1 activity. This correla-
tive evidence supports that the increased NAD+ availability might
be a key mechanism by which PARP deﬁciency activates SIRT1
(Bai et al., 2011). However, more studies are needed to establish
direct regulation of SIRT1 activity by the relatively small magni-
tude changes in cytosolic NAD concentrations that occur under
physiological conditions.
FIGURE 2 | Anti-inflammatory mechanisms of SIRT1. SIRT1 deacetylates
p65 and blocks the transactivation of NF-κB-dependent gene expression.
SIRT1 suppresses the activity of PARP-1, a coactivator of NF-κB-dependent
transcription, by deacetylation and by inhibiting its expression. PARP-1
activation could deplete NAD+, resulting in inhibition of SIRT1 and NF-κB
activation. On the epigenetic level, SIRT1 represses NF-κB-dependent
inﬂammatory gene expression by deacetylating H4K16 and also by recruiting
more components of repressor complexes. SIRT1 deacetylates and activates
histone methyltransferase SUV39H1, which suppresses expression of inducible
inﬂammatory genes. DNA methylation is associated with suppressed
expression.Whether SIRT1 could inhibit expression of inﬂammatory genes by
enhancing promoter methylation remains to be determined.
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Inﬂammatory responses are regulated by epigenetic changes
(Medzhitov and Horng, 2009), which are deﬁned as mitotically
and meiotically heritable changes in gene function that do not
depend on DNA sequence (Bernstein et al., 2007). SIRT1 deacety-
lates and inactivates the transactivation state of p65, deacetylates
speciﬁc lysines on histone H3 and H4, H1 nucleosome linker, and
histone methyltransferase suppressor of variegation 3–9 homolog
1 (SUV39H1); andmodulates activities of DNACpGmethyltrans-
ferases (McCall et al., 2011). Additionally, SIRT1 could deacetylate
and inactivate p300/CBP,critical coactivators of NF-κB-dependent
expression of inﬂammatory genes (Chen and Greene, 2003). A
number of epigeneticmechanisms are involved in SIRT1-mediated
regulation of inﬂammatory responses (Figure 2).
HISTONE ACETYLATION
SIRT1 might repress inﬂammatory responses by combining
deacetylation of histones and recruitment of non-histone proteins,
such as p65/RelA (Liu et al., 2011). During endotoxin tolerance
when transition from hyperinﬂammation to hypoinﬂammation
occurs, SIRT1 deacetylates H4K16 to terminate NF-κB-dependent
transcription. SIRT1 represses gene expression by deacetylating
histones and also by remaining bound to TNFα and IL-1β pro-
moter regions to recruitmore components of repressor complexes,
such as histone H1, RelB, and methyltransferases (Liu et al., 2011;
Figure 2).
HISTONE METHYLATION
Unlike histone acetylation, which is associated with active tran-
scription, histone methylation is often associated with transcrip-
tional repression (Bernstein et al., 2007). SIRT1 could suppress
expression of inﬂammatory genes by enhancing the activities
of histone methyltransferases. For example, SIRT1 deacetylates
and activates histone methyltransferase SUV39H1, resulting in
increased levels of the trimethylH3K9 (Vaquero et al., 2007),which
suppresses expression of inducible inﬂammatory genes (Saccani
and Natoli, 2002; Figure 2).
DNA METHYLATION
Inﬂammatory gene expression could be regulated by methylation
of CpG sites on the promoter region,which is often associatedwith
transcriptional repression (Hartnett and Egan, 2012). For exam-
ple, DNA methylation of IL1β inversely correlated with the levels
of mRNA(Hashimoto et al., 2013). Since SIRT1 alsomodulates the
activities of DNAmethyltransferases (Peng et al., 2011), it remains
to be determined if SIRT1 suppresses inﬂammatory responses via
increasingmethylationof promoter regions of inﬂammatory genes
(Figure 2).
Hyperactive NF-κB signaling in SIRT6-deﬁcientmice is impor-
tant for the premature aging phenotype (Kawahara et al., 2009).
In SIRT6-deﬁcient cells, hyperacetylation of H3K9 at these target
promoters is associated with increased RelA promoter occupancy
and enhanced NF-κB-dependent modulation of gene expression,
apoptosis, and cellular senescence (Kawahara et al., 2009). Partial
inactivation of NF-κB ameliorated the premature aging phenotype
in SIRT6 KOmice (Kawahara et al., 2009). Thus, continuedNF-κB
activation is required to enforce many features of aging. Interest-
ingly, overexpression of SIRT6 in male mice, but not in female
mice, resulted in signiﬁcantly longer lifespan than wild-type mice
(Kanﬁ et al., 2012). Male mice overexpressing SIRT6 had lower
serum levels of insulin-like growth factor 1 (IGF1), a key path-
way for regulating lifespan (Kenyon, 2010). Thus, SIRT6 could
promote longevity via multiple downstream signaling pathways.
CONCLUSION AND THERAPEUTIC PERSPECTIVES
Sirtuins block multiple key processes in neurodegeneration. They
restore protein homeostasis by reducing accumulation of toxic
protein aggregates, improve neural plasticity by elevating tran-
scription of genes important for learning and memory, enhance
mitochondria function by reducing oxidative stress, and suppress
sustained chronic inﬂammation via inhibiting NF-κB combined
with epigenetic mechanisms.
However, it is important to recognize that the effects and regula-
tion of sirtuins are extremely complex. Broad activation of sirtuins
will lead to deacetylation of histones and various non-histone pro-
teins, which may affect diverse cellular functions. For example,
SIRT1 and SIRT2 appear to have opposite effects on the aggrega-
tion of misfolded proteins. Activation of a given sirtuin may have
divergent outcomes, depending on pathophysiological circum-
stances. Nevertheless, speciﬁc sirtuinmodulators could have broad
therapeutic potential against various neurodegenerative diseases.
There has been an intense debate surrounding the importance
of sirtuin enzymes inmediating the effects of resveratrol and other
small-molecule compounds that activate SIRT1-related pathways
(see Baur et al., 2012 for a comprehensive review on this topic).
More studies will be needed to resolve the discrepancies and to
develop new SIRT1 activators that can pass the blood–brain bar-
rier and improve CNS functions in models of neurodegenerative
diseases.
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